Генетический полиморфизм и фармакокинетика лекарственных средств
Аннотация
Об авторах
И. И. МирошниченкоРоссия
С. Н. Птицина
Россия
Список литературы
1. Евгеньев М. И., Гармонов С. Ю., Погорельцев В. И. и др. Определение фенотипа ацетилирования для терапевтического мониторинга лекарственных средств. Клин лаб диагностика 1996; 5: 24-27.
2. Середенин С. Б., Вальдман Е. А. Фармакология и генетика. Новые перспективы и возможности. Вестник РГМУ 2003; 4: 30: 75-77.
3. Brosen K., Gram L. F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537—547.
4. Buck M. L. The cytochrome P450 enzyme system and its effect on drug metabolism. Pediatr Pharmacother 1997; 3: 5: 211-216.
5. Dahl M. L. Cytochrome P450 phenotyping in patients receiving antipsychotics. Useful aid to prescribing? Clin Pharmacokin 2002; 41: 453-470.
6. Flexner C. W. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top HIV Med 2003; 11: 2: 40-44.
7. Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part I. Current Separations BAS 2000; 19: 1: 17-23.
8. Hashimoto Y, Nakayama T. Futamura A. et al. Relationship between genetic polymorphisms of alcohol-metabolizing enzymes and changes in risk factors for coronary heart disease associated with alcohol consumption. Clin Chem 2002; 48: 7: 1043-1048.
9. Harris C. C. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1989; 10: 1563—1566.
10. Ji L., Pan S., Marti-Jaun J. et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002;48: 7: 983-988.
11. Kawajiri K., Nakachi K., Imai K. et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131—133.
12. Kidd R. S., Straughn A. B., Meyer M. C. et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9: 1: 71-80.
13. Kurata Y., Ieiri I., Kimura M. et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.
14. Kwan K. C. Oral bioavailability and first-pass effects. Drug Metab Dispos 1997; 25: 12: 1329-1336.
15. Linder M. W., Prough R. A., Valdes R. Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997; 43: 2: 254-266.
16. Linder M. W., Valdes R. Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001; 25: 5: 405-413.
17. Maiorana A., Roach R. B. Jr. Heterozygous pseudocholinesterase deficiency: a case report and review of the literature. J Oral Maxillofac Surg. 2003; 61: 7: 845-847.
18. Meyer J. M., Rodvold K. A. Drug biotransformation by the cytochrome P-450 enzyme system. Infect Med 1996; 13: 6: 452, 459, 463-464, 523.
19. Nakachi K., Imai K., Hayashi S., Watanabe J. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51: 5177—5180.
20. Rettie A. E., Wienkers L. C., Gonzalez F. J. et al. Impaired (S) -warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4: 39—42.
21. Rogers J. F., Nafziger A. N., Bertino J. S. Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 9: 746-750.
22. Weber W. W. Populations and genetic polymorphisms. Mol Diagn – 1999; 4: 4: 299-307.
Рецензия
Для цитирования:
Мирошниченко И.И., Птицина С.Н. Генетический полиморфизм и фармакокинетика лекарственных средств. Клиническая фармакокинетика. 2005;(2):35-39.